Department of Clinical Laboratory, Peking University People's Hospital, Beijing 100044, China.
J Antimicrob Chemother. 2020 Sep 1;75(9):2609-2615. doi: 10.1093/jac/dkaa217.
SPR206 is a novel polymyxin analogue. Activity against clinical isolates is little documented.
A collection of 200 MDR, carbapenem-resistant, tigecycline-resistant, colistin-resistant and non-MDR clinical isolates of Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae and Stenotrophomonas maltophilia was obtained from 50 centres across China (2016-17). All isolates were derived from respiratory tract, urine and blood samples. Strains were purposely selected on the basis of phenotypes, genotypes and specimen origins. MICs of SPR206 and other antimicrobials were determined.
SPR206 was active against all bacteria tested except colistin-resistant isolates. The MIC50/90 values of SPR206 for colistin-resistant strains were comparable to known polymyxins (16/128 versus 8/128 mg/L). SPR206 exhibited potent activity against colistin-susceptible OXA-producing A. baumannii (MIC50/90 = 0.064/0.125 mg/L), NDM-producing Enterobacteriaceae (MIC50/90 = 0.125/0.25 mg/L) and KPC-2-producing Enterobacteriaceae (MIC50/90 = 0.125/0.5 mg/L). In fact, SPR206 was the most potent agent tested, with 2- to 4-fold lower MICs than colistin and polymyxin B for A. baumannii, P. aeruginosa and Enterobacteriaceae. Additionally, MIC values of SPR206 (MIC50/90 = 0.064/0.125 mg/L) were 16- to 32-fold lower than those of tigecycline (MIC50/90 = 2/2 mg/L) for tigecycline-susceptible carbapenem-resistant A. baumannii.
SPR206 showed good in vitro activity against MDR, tigecycline-resistant and non-MDR clinical isolates of Gram-negative pathogens. SPR206 also exhibited superior potency to colistin and polymyxin B, with 2- to 4-fold lower MIC50/90 values.
SPR206 是一种新型多粘菌素类似物。针对临床分离株的活性很少有文献记载。
从中国 50 个中心（2016-17 年）获得了 200 株耐多药、碳青霉烯类耐药、替加环素耐药、多粘菌素耐药和非耐多药的鲍曼不动杆菌、铜绿假单胞菌、肺炎克雷伯菌、大肠埃希菌、阴沟肠杆菌和嗜麦芽窄食单胞菌的临床分离株。所有分离株均来自呼吸道、尿液和血液样本。根据表型、基因型和标本来源，有目的地选择菌株。测定 SPR206 和其他抗菌药物的 MIC。
SPR206 对除多粘菌素耐药株外的所有测试细菌均有活性。SPR206 对多粘菌素耐药株的 MIC50/90 值与已知多粘菌素相当（16/128 与 8/128 mg/L）。SPR206 对多粘菌素敏感的产 OXA 鲍曼不动杆菌（MIC50/90=0.064/0.125 mg/L）、产 NDM 的肠杆菌科（MIC50/90=0.125/0.25 mg/L）和产 KPC-2 的肠杆菌科（MIC50/90=0.125/0.5 mg/L）具有强大的活性。事实上，SPR206 是测试中最有效的药物，其 MIC 比多粘菌素和多粘菌素 B 低 2-4 倍，用于鲍曼不动杆菌、铜绿假单胞菌和肠杆菌科。此外，SPR206 的 MIC 值（MIC50/90=0.064/0.125 mg/L）比替加环素（MIC50/90=2/2 mg/L）低 16-32 倍，用于替加环素敏感的耐碳青霉烯类鲍曼不动杆菌。
SPR206 对革兰氏阴性病原体的 MDR、替加环素耐药和非 MDR 临床分离株表现出良好的体外活性。SPR206 还表现出优于多粘菌素和多粘菌素 B 的效力，其 MIC50/90 值低 2-4 倍。
